A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

  • STATUS
    Recruiting
  • End date
    May 29, 2026
  • participants needed
    5000
  • sponsor
    Novartis Pharmaceuticals
Updated on 25 October 2020
Investigator
Novartis Pharmaceuticals
Primary Contact
Novartis Investigative Site (0.1 mi away) Contact
+343 other location

Summary

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer

Details
Treatment Ribociclib, Endocrine Therapy
Clinical Study IdentifierNCT03701334
SponsorNovartis Pharmaceuticals
Last Modified on25 October 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have Early Breast Cancer?
Patient is 18 years-old at the time of PICF signature
Patient is female with known menopausal status at the time of randomization or initiation of adjuvant ET (whichever occurs earlier), or male
Patient with histologically confirmed unilateral primary invasive adenocarcinoma of the breast with a date of initial cytologic or histologic diagnosis within 18 months prior to randomization
Patient has breast cancer that is positive for ER and/or PgR
Patient has HER2-negative breast cancer
Patient has available archival tumor tissue from the surgical specimen
Patient after surgical resection where tumor was removed completely, with the final surgical specimen microscopic margins free from tumor, and belongs to one of the following categories: anatomic stage group II or III
If indicated, patient has completed adjuvant and/or neoadjuvant chemotherapy according to the institutional guidelines
If indicated, patient has completed adjuvant radiotherapy according to the institutional guidelines
Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Patient has no contraindication for the adjuvant ET in the trial and is planned to be treated with ET for 5 years

Exclusion Criteria

Patient has received any CDK4/6 inhibitor
Patient has received prior treatment with tamoxifen, raloxifene or AIs for reduction in risk ("chemoprevention") of breast cancer and/or treatment for osteoporosis within the last 2 years prior to randomization. Patient is concurrently using hormone replacement therapy
Patient has received prior treatment with anthracyclines at cumulative doses of 450 mg/m or more for doxorubicin, or 900 mg/m or more for epirubicin
Patient with a known hypersensitivity to any of the excipients of ribociclib and/or ET
Patient with distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative surgery
Patient is concurrently using other anti-neoplastic therapy with the exception of adjuvant ET
Patient has had major surgery, chemotherapy or radiotherapy within 14 days prior to randomization
Patient has not recovered from clinical and laboratory acute toxicities related to prior anti-cancer therapies
Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 2 years before randomization
Patient has known HIV infection, Hepatitis B or C infection
Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality
Patient is currently receiving any of the following substances within 7 days before randomization - Concomitant medications, herbal supplements, and/or fruits that are known as strong inhibitors or inducers of CYP3A4/5 or Medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5
is currently receiving or has received systemic corticosteroids 2 weeks prior to starting trial treatment
Patient has impairment of GI function or GI disease that may significantly alter the absorption of the oral trial treatments
Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol
Participation in other studies involving investigational drug(s) within 30 days prior to randomization or within 5 half-lives of the investigational drug(s) (whichever is longer), or participation in any other type of medical research judged not to be scientifically or medically compatible with this trial
Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet